Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : angelMD Invests in Two Startups from the Johnson & Johnson QuickFire Challenge

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 03:37pm CEST

Seattle, Washington (PRWEB) October 05, 2017

Today, angelMD, the world's largest network of healthcare startups, announced investments in LifeSprout and Intelligent Implants, two promising startups identified through angelMD's collaboration with Johnson & Johnson Innovation on the "QuickFire Challenge" competition.

In conjunction with the upcoming grand opening of Johnson & Johnson Innovation's Center for Device Innovation at the Texas Medical Center in Houston (CDI @ TMC), Johnson & Johnson Innovation launched the CDI @ TMC QuickFire Challenge with angelMD to challenge startups to develop early-stage medical device innovations. The CDI @ TMC is the second Johnson & Johnson Innovation facility in Houston, joining the already established JLABS @ TMC.

"Identifying the best science and technology in healthcare is one of our goals at Johnson & Johnson Innovation," said Tom Luby, head of Johnson & Johnson' Innovation's startup accelerator in Houston, JLABS @ TMC. "Joining with partners like angelMD in startup challenges, we hope to find early-stage companies creating new innovations in healthcare, and we will work with these startups to further support their development."

As part of the collaboration with Johnson & Johnson Innovation, the angelMD Catalyst Fund will make a $50,000 investment each in LifeSprout and Intelligent Implants. In addition, angelMD will feature the two startups on its investment platform for angelMD members to invest an additional $250,000 or more in each company. The investments were officially announced by Charlie Emley, Catalyst Fund Managing Partner, at the 2017 MedTech Conference in San Jose, California.

"As the largest network of healthcare startups in the world, we see first-hand the innovation taking place among startups working to create better healthcare outcomes," said Tobin Arthur, co-founder and chief executive officer for angelMD. "We are honored to partner with Johnson & Johnson Innovation's JLABS facility to help identify some of the most promising medical device startups, and we are excited to invest in LifeSprout and Intelligent Implants."

LifeSprout is a startup formed by Russell Martin, Hai-Quan Mao, Justin Sacks, and Dr. Sashank Reddy. Together, this group of engineers, scientists, and clinicians from Johns Hopkins University developed an innovative soft tissue replacement alternative. This synthetic alternative can be used to replace soft tissue lost as a result of various cancers or traumatic incidents.

Intelligent Implants is a startup founded by John Zellmer, Erik Zellmer, Juan Pardo, and Rory Murphy. The team worked to harness the latest advances in electro-therapeutics to speed up, control and monitor bone growth. The Intelligent Implants system is known as "SmartFuse" and represents a novel method of delivering electric current to support the process of bone fusion. With SmartFuse, they can stimulate more where they want bone growth, and stimulate less where it's not needed.

"LifeSprout and Intelligent Implants represent some of the most innovative thinking in healthcare today, and we are excited to invest in these companies' futures," added Arthur. "angelMD will continue to help spur innovation in healthcare by being a partner to ground-breaking startups such as these."

In addition to the CDI @ TMC QuickFire Challenge, angelMD plans to host another startup competition at its upcoming Alpha Conference. More information about the Alpha Conference can be found at: http://www.alphatheconference.com/.

About angelMD
angelMD is an investment platform and marketplace connecting innovative medical startups, physicians, investors and industry partners. Leading physicians from all over the US have joined the angelMD Scientific Advisory Board and Leaders Club to help source, evaluate and advise companies in biotechnology, medical device and healthcare technology. For more information, visit http://www.angelmd.co.

Read the full story at http://www.prweb.com/releases/2017/10/prweb14761625.htm

(c) 2017 PRWEB.COM Newswire, source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
06:27p JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
05:54p JOHNSON & JOHNSON : Judge throws out another talc verdict against Johnson & John..
05:37a JOHNSON & JOHNSON : California judge tosses $417 mln talc cancer verdict against..
04:22a JOHNSON & JOHNSON : Judge tosses $417M award against Johnson & Johnson
01:47a JOHNSON & JOHNSON : Janssen receives two u.s. fda approvals for simponi aria® (g..
10/20 JOHNSON & JOHNSON : Ryan Tedder, Hamdi Ulukaya, Bulgari North America Honored at..
10/20 JOHNSON & JOHNSON : blames price cuts in India for poor show in knee-implant bus..
10/20 Healthcare looking in good shape
10/19 JOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. Food and Drug A..
10/19 JOHNSON & JOHNSON : The Fastest Growing Regions for Dermatological Drug Sales Ar..
More news
News from SeekingAlpha
09:00a 3 THINGS, OCTOBER 21, 2017 : Celgene's New Gamble, Pluristem Marches On ARS, Jan..
10/20 FDA OKs expanded uses for J&J's Simponi Aria
10/20 The Best DGI Stocks For Young Investors - October 1-12, 2017
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 JOHNSON & JOHNSON : Create Your Own Dividends
Financials ($)
Sales 2017 76 267 M
EBIT 2017 23 526 M
Net income 2017 15 953 M
Debt 2017 16 641 M
Yield 2017 2,35%
P/E ratio 2017 24,46
P/E ratio 2018 19,91
EV / Sales 2017 5,23x
EV / Sales 2018 4,84x
Capitalization 382 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 144 $
Spread / Average Target 1,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223
AMGEN27.41%133 501